Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
FDA Approval: Pembrolizumab, in combination with platinum- and fluoropyrimidine-based chemotherapy, is FDA-approved for advanced esophageal carcinoma. The specific regimen includes pembrolizumab + cisplatin + fluorouracil (5-FU). Approval date: March 22, 2021. Applicable for metastatic or locally advanced esophageal or gastroesophageal junction carcinoma, not suitable for surgical resection or definitive chemoradiation. KEYNOTE-590 study: Pembrolizumab + cisplatin + fluorouracil vs. placebo + cisplatin + fluorouracil (1)
[EMA Authorization:](brain://QMGe2vnxWkWiArAahJp9aA/EuropeanMedicinesAgencyE…